Hemophilia

Inhibitors in hemophilia A tend to be managed by immune tolerance approaches

Published in Blood Weekly, September 25th, 2003

Antibodies to factor VIII require alternative treatment of hemophiliacs; the most common practices involve ways to induce immune tolerance.

According to recent research published in the journal Haemophilia, "Hemophilia is the commonest bleeding disorder in the U.K., affecting approximately 5400 people, almost all of them male. In hemophiliacs, reduced levels, or absence, of factor VIII (FVIII) causes bleeding episodes, typically into joint spaces or muscles. Hemophilia is generally treated with exogenous FVIII.

"However, in some hemophiliacs, therapeutically administered FVIII comes to be recognized as a foreign protein, stimulating the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-09-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry